Jaguar Health's Crofelemer Reduces Daily Parenteral Support Needs by About 15% in Infant With Congenital Sodium Diarrhea

• Jaguar Health reported reduced intravenous nutritional support needs with oral crofelemer in an infant with intestinal failure caused by congenital sodium diarrhea.
• Treatment was well tolerated, with no significant clinical or laboratory abnormalities during the first several weeks.
• The findings extend crofelemer's observed benefit to a third intestinal failure-related disorder under expanded access.
• Earlier findings presented in June 2026 showed reduced support needs in pediatric microvillus inclusion disease and short bowel syndrome.
• A US approval application for microvillus inclusion disease is planned for mid-2027; the ongoing pivotal trial has completed enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610210900ACCESSWRNAPR_____1239113) on October 21, 2026, and is solely responsible for the information contained therein.